IRVINE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host its inaugural Lap-Band® Surgeon Summit, taking place August 1-3, 2025 in Nashville, Tennessee. Dr. Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of the NYU Langone Weight Management Program, and Chief of the Division of Bariatric Surgeons, will direct the Summit, whe ...

Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys Shareholders are encouraged to vote FOR Proposals 1, 2, and 3 by Calling 1-877-750-8310 IRVINE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host a Special Meeting of Stockholders of ReShape Lifesciences Inc. to be held at 11:30 am ET ...

Core Insights - ReShape Lifesciences announced the issuance of U.S. Patent 12,350,179 for an intragastric device, enhancing its intellectual property portfolio [1][2] - The patent covers a swallowable capsule with a self-sealing fill valve and a degradable release valve, designed for natural excretion after deflation [1] - The patent protection extends to at least January 2031, potentially longer with a Patent Term Extension [1] Intellectual Property Development - The company has secured over 50 patents related to its intragastric balloon technology since its initial filing in 2011, contributing to a total of over 160 issued and pending patents [2] - This robust patent portfolio positions the company to defend its competitive edge and support its innovation pipeline [2] Company Overview - ReShape Lifesciences specializes in weight loss and metabolic health solutions, offering products like the FDA-approved Lap-Band systems and the non-surgical Obalon balloon technology [3] - The company aims to provide integrated solutions for managing obesity and metabolic diseases [3] Recent Transactions - ReShape has entered into an asset purchase agreement with Biorad Medisys, agreeing to sell substantially all of its assets, including the Lap-Band and Obalon systems [4]

Core Points - ReShape Lifesciences Inc. has regained compliance with Nasdaq's stockholders equity requirement, closing the listing matter [1][2] - The company previously faced potential delisting due to non-compliance with the minimum stockholders' equity requirement of $2.5 million [2] - As of March 31, 2025, the company's stockholders' equity was reported at $1.2 million [3] - The company raised a total of approximately $6.3 million through the sale of common stock in June 2025, which helped it regain compliance [3] Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products and services for obesity and metabolic disease management [4] - The company provides the FDA-approved Lap-Band® System, which is a minimally invasive treatment for obesity [4] - Other offerings include an investigational vagal neuromodulation system for type 2 diabetes and metabolic disorders, and the non-surgical Obalon® balloon technology for weight loss [4]

Core Insights - ReShape Lifesciences Inc. announced a strategic headcount reduction aimed at saving over $750,000 annually, which represents approximately 23.4% of its payroll expenses [1][2] - The company is progressing towards finalizing a merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys, with a special shareholder meeting scheduled for July 24, 2025, to vote on these transactions [1][2] Company Overview - ReShape Lifesciences is a leading provider of weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band System, which provides a minimally invasive treatment for obesity [3] - The company also has investigational products such as a vagal neuromodulation system for type 2 diabetes and the Obalon balloon technology for non-surgical weight loss [3] Strategic Focus - The company aims to maintain its core capabilities while enhancing operational efficiency through workforce reduction, ensuring that its sales and marketing team remains intact to drive patient leads via digital marketing [2] - ReShape is also focusing on international expansion efforts in Canada through a distribution agreement with Liaison Medical to launch the enhanced Lap-Band 2.0 FLEX [2]

Core Insights - ReShape Lifesciences has been granted an international patent for its Diabetes Neuromodulation technology, which aims to improve glycemic control in Type 2 diabetes patients [1][2] - The technology utilizes a proprietary vagus nerve block (vBloc™) system combined with bioelectronic modulation to manage glucose levels effectively [2][3] - The patent protection extends until April 12, 2039, enhancing the company's intellectual property position and commercial prospects [1][2] Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band® systems and Obalon® balloon technology [4] - The company is focused on innovative approaches to treat obesity and metabolic diseases, with a strong emphasis on personalized medicine [3][4] Technology Details - The Diabetes Neuromodulation system is designed to deliver targeted electrical signals to regulate insulin release and glucose levels, showing promise in preclinical studies [2][3] - The system is considered superior to traditional vagus nerve stimulation methods, as it minimizes side effects and allows for adjustable treatment [3] Market Position - The granting of the Australian patent is seen as a significant milestone that underscores the global relevance of the company's technology and its potential to reduce reliance on daily medications for diabetes management [2] - ReShape Lifesciences holds a robust intellectual property portfolio with 63 issued or pending patents, covering various aspects of its technology [2]

PENDING MERGER $RSLS TO $HIND CORPORATE PRESENTATION DECEMBER 2024 Vyome A US-India healthcare platform with clinical-stage immuno-inflammation assets VYOME THERAPEUTICS, INC. ("Vyome") Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," and simila ...

Core Insights - ReShape Lifesciences has signed an exclusive U.S. distribution agreement with Recon Supply to distribute its medical products to U.S. veterans and active-duty service members [1][2] - The partnership aims to enhance access to innovative medical technologies, including the STIMEL-03 neuromuscular rehabilitation device and the Lap-Band® 2.0 FLEX [2] - Recon Supply has experienced significant growth, with a 113% year-over-year increase since its relaunch in 2022, and now distributes to 102 VA Medical Centers nationwide [2] Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of FDA-approved products for obesity management [4] - The company’s portfolio includes the Lap-Band® System, a minimally invasive treatment for obesity, and other innovative technologies aimed at treating metabolic disorders [4] - Recon Supply is a Service-Disabled Veteran-Owned Small Business (SDVOSB) focused on delivering high-quality medical solutions while supporting the veteran community [3]

Core Viewpoint - ReShape Lifesciences has announced a public offering of 1,054,604 shares of common stock at a price of $2.50 per share, expecting gross proceeds of approximately $2.6 million before expenses [1]. Group 1: Offering Details - The public offering is being conducted under an effective shelf registration statement filed with the SEC, which was declared effective on May 14, 2025 [3]. - Maxim Group LLC is acting as the sole placement agent for this offering [2]. - The offering is expected to close on or about June 9, 2025, pending customary closing conditions [1]. Group 2: Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products and services for obesity and metabolic disease management [4]. - The company’s FDA-approved products include the Lap-Band® systems, which provide minimally invasive treatment options for obesity, and the ReShape Diabetes Neuromodulation system, which targets glucose regulation [4]. - The Obalon® balloon technology is another innovative product that offers a non-surgical method for weight loss [4].

Core Insights - ReShape Lifesciences has achieved certification for its Quality Management System (QMS) and medical devices under the EU Medical Device Regulation (MDR) and UK Conformity Assessment (UKCA), ahead of the December 31, 2027 deadline [1][3] - The EU MDR, effective since May 2021, imposes stricter requirements for clinical evaluation, post-market surveillance, and device traceability to enhance patient safety and product quality across the European Economic Area [2] - The certification positions ReShape Lifesciences among a select group of manufacturers compliant with the EU's rigorous standards, enabling the company to expand its product pipeline and maintain market access in Europe [3] Company Overview - ReShape Lifesciences specializes in weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band System and investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system [4] - The company’s offerings include non-surgical options like the Obalon balloon technology, designed for long-lasting weight loss [4]